Endocyte, Inc.
(NASDAQ : ECYT)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -0.50%43.970.9%$1186.44m
ABBVAbbVie, Inc. -0.22%107.121.9%$1023.77m
JNJJohnson & Johnson -0.23%164.480.7%$988.09m
MRKMerck & Co., Inc. 0.81%73.640.7%$914.30m
LLYEli Lilly & Co. -0.26%231.581.1%$588.95m
BMYBristol-Myers Squibb Co. -0.61%60.261.0%$575.61m
AZNAstraZeneca Plc 1.46%60.351.0%$353.10m
NVSNovartis AG -0.75%82.950.2%$156.40m
CRVSCorvus Pharmaceuticals, Inc. -3.27%6.800.7%$140.27m
GSKGlaxoSmithKline Plc -2.44%38.380.2%$135.32m
RGENRepligen Corp. -0.29%323.266.8%$123.14m
SNYSanofi -1.60%47.940.2%$122.20m
RPRXRoyalty Pharma Plc -0.08%37.100.1%$121.13m
VTRSViatris, Inc. 0.30%13.380.0%$107.54m
NVONovo Nordisk A/S -1.36%100.710.1%$101.76m

Company Profile

Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.